Capital International Investors Boosts Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Investors lifted its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 3.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 5,046,058 shares of the company’s stock after acquiring an additional 161,052 shares during the period. Capital International Investors’ holdings in BeOne Medicines were worth $1,716,883,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ONC. Anchor Investment Management LLC purchased a new stake in BeOne Medicines in the second quarter valued at approximately $26,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter worth approximately $35,000. EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines during the second quarter worth approximately $68,000. Steward Partners Investment Advisory LLC acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $169,000. Finally, Montag A & Associates Inc. acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $182,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ONC. Citigroup upped their price objective on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Barclays raised their price target on shares of BeOne Medicines from $394.00 to $405.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Truist Financial increased their price objective on shares of BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Morgan Stanley reissued an “overweight” rating and issued a $405.00 target price on shares of BeOne Medicines in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada upped their price target on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $401.00.

Insider Buying and Selling

In other BeOne Medicines news, CEO John Oyler sold 24,369 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $302.87, for a total transaction of $7,380,639.03. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 102,656 shares of company stock valued at $31,567,496 in the last three months. Corporate insiders own 6.62% of the company’s stock.

BeOne Medicines Trading Up 0.4%

NASDAQ ONC opened at $302.29 on Tuesday. The stock has a market cap of $33.15 billion, a P/E ratio of 119.96 and a beta of 0.53. The company’s fifty day simple moving average is $335.51 and its 200-day simple moving average is $330.31. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $196.45 and a 52 week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. Equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current fiscal year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.